Business Context and Reporting Period
This Form 8-K Current Report was filed by enVVeno Medical Corporation (NVNO) on May 19, 2025. The filing reports significant changes in executive leadership, specifically the appointment of a new Chief Financial Officer and the resignation of the previous CFO.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and employment terms.
Material Changes
Appointment of Chief Financial Officer
- New CFO: Jennifer Bright was appointed Chief Financial Officer effective May 19, 2025.
- Compensation:
- Annual Base Salary: $300,000.
- Annual Bonus: Eligible for up to 40% of base salary.
- Equity Grant: 350,000 stock options at an exercise price of $3.62 per share.
- Vesting Schedule: Quarterly over three years with a one-year cliff.
- Severance Terms: In the event of termination without "Cause" or resignation for "Good Reason," Ms. Bright is entitled to three months of severance for each year of employment, capped at one year of total severance, plus accrued benefits.
Resignation of Chief Financial Officer
- Outgoing CFO: Craig Glynn resigned as Chief Financial Officer effective May 19, 2025.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Transition Plan: Mr. Glynn is expected to enter into a consulting agreement to assist with the orderly transition of CFO responsibilities.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies related to financial operations were disclosed in this report, other than the standard transition of executive duties.
Investor Verification Checklist
- Verify the exact terms of the consulting agreement to be entered into with outgoing CFO Craig Glynn.
- Review the full text of the Employment Agreement with Jennifer Bright, which will be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2025.
- Confirm the impact of the leadership change on the Company's upcoming financial reporting cycle.
- Monitor the vesting schedule and exercise price ($3.62) of the 350,000 options granted to the new CFO relative to current market prices.